GICS Sector : Healthcare
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease.The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system.It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19.
Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.
Intech Investment Management LLC Buys 6,141 Shares of Immunome, Inc. $IMNM
Dec -01
Immunome to Present at Upcoming Investor Conferences
Nov -25
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov -04
Brighton Jones LLC Invests $98,000 in Immunome, Inc. $IMNM
Nov -02
Immunome Presents Preclinical Data Showing Proprietary TOP1i ADC Payload HC74 Overcomes Multiple Mechanisms of ADC Resistance
Oct -23
KLP Kapitalforvaltning AS Has $123,000 Holdings in Immunome, Inc. $IMNM
Oct -22
Immunome, Inc. (NASDAQ:IMNM) Given Average Recommendation of “Moderate Buy” by Analysts
Oct -22
Immunome (IMNM) Surges 6.1%: Is This an Indication of Further Gains?
Sep -25
Immunome, Inc.'s 10.55% growth in Biotechnology is driven by increasing demand for targeted therapies, advancements in gene editing technologies, and a strong pipeline of novel immunotherapies. Additionally, strategic partnerships and collaborations are fueling innovation and expanding market reach, contributing to the company's rapid growth.
IMM-101 is a therapeutic antibody cocktail designed to treat COVID-19. It is a combination of three antibodies that target the SARS-CoV-2 virus.
IMM-201 is a therapeutic antibody cocktail designed to treat cancer. It targets specific tumor-associated antigens and activates the immune system to fight cancer cells.
IMM-301 is a diagnostic platform that uses proprietary antibody-based technology to detect and diagnose infectious diseases, including COVID-19.
Immunome, Inc. has a moderate threat of substitutes due to the presence of alternative treatments and therapies for cancer and infectious diseases.
Immunome, Inc. has a low bargaining power of customers due to the specialized nature of its products and services, which limits the ability of customers to negotiate prices.
Immunome, Inc. has a moderate bargaining power of suppliers due to the availability of multiple suppliers for raw materials and services, but the company's dependence on a few key suppliers for critical components.
Immunome, Inc. has a high threat of new entrants due to the attractiveness of the biotechnology industry and the potential for new companies to enter the market with innovative products and services.
Immunome, Inc. operates in a highly competitive industry with many established players, leading to a high intensity of rivalry among companies.
| Value | |
|---|---|
| Debt Weight | 1.36% |
| Debt Cost | 3.95% |
| Equity Weight | 98.64% |
| Equity Cost | 13.35% |
| WACC | 13.22% |
| Leverage | 1.38% |
Value: 0.2
Growth: 9.4
Quality: 8.0
Yield: 0.0
Momentum: 8.0
Volatility: 2.3
1-Year Total Return ->
Value: 6.2
Growth: 5.0
Quality: 4.3
Yield: 0.0
Momentum: 6.0
Volatility: 2.3
1-Year Total Return ->
Value: 4.2
Growth: 4.6
Quality: 4.1
Yield: 0.0
Momentum: 10.0
Volatility: 0.0
1-Year Total Return ->
Value: 6.0
Growth: 6.4
Quality: 4.2
Yield: 0.0
Momentum: 5.0
Volatility: 0.3
1-Year Total Return ->
Value: 6.4
Growth: 5.1
Quality: 4.7
Yield: 0.0
Momentum: 4.0
Volatility: 1.3
1-Year Total Return ->
Value: 6.0
Growth: 7.9
Quality: 4.7
Yield: 0.0
Momentum: 2.5
Volatility: 0.0
1-Year Total Return ->